Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi

Chauhan A, Samnaliev M, Ken-Opurum J, Sai Srinivas S, Mehta AM, Dex T, Charland S, Revel A, Preblick R

About 37.3 million people in the US have Type 2 Diabetes Mellitus (T2DM), accounting for more than 95% of all diabetes cases. The objective of this study was to identify two real-world cohorts of individuals with T2DM from an integrated claims and EHR database who meet the criteria for treatment with iGlarLixi and apply a Monte Carlo simulation to mirror the treatment arms in the LixiLan-O and LixiLan-L trials, thus evaluating the clinical benefits of iGlarLixi in these patients.

Contact us at insights@axtria.com with any questions.